Based on statistics from the World Bank, the United States government spent 3.59 percent of its 2022 gross domestic product on research and development. While private businesses spend on their own research and development costs, it’s important for businesses to treat these expenditures appropriately.
When it comes to research and development outlays, U.S. Generally Accepted Accounting Principles (GAAP) dictate that businesses must expense them during the identical fiscal year as they’re consumed. Accordingly, this creates difficulties for investors and business owners alike in two ways. The first is more uncertain profitability and loss projections. The second is a murkier ability to quantify their rates of return on assets and investments.
If R&D capitalization is minimal or non-existent by a company, it can imply the business’ total assets (or its total invested capital) doesn’t accurately represent how much has been put into such assets. This will affect the business’ Return on Assets (ROA) and Return on Invested Capital (ROIC). This illustrates the importance in differences of how businesses treat their R&D expenses – using the balance sheet to capitalize and the income statement to expense.
Accounting Standards
Per International Financial Reporting Standards (IFRS), research outlays are classified as expenses annually, like GAAP. However, development costs may be capitalized for businesses with assets under incubation for saleable purposes (in other words, the tech/IP is expected to be approved and produce revenue in the future).
One consideration with IFRS is that a portion of research and development costs may be capitalized or recorded as an asset on the business’ balance sheet, instead of classified as an expense on the Profit and Loss Statement. It’s important, though, to understand that judgment is in the eye of the classification as to how commercially viable a product or service will be in the future, potentially causing issues on the company’s financial statements. Since research and development is sporadic, it impacts a business’ profitability. It’s seen in certain sectors, such as consumer discretionary, healthcare, and technology, to highlight a few.
With revenue, cash flow, and profit expected from the long-term investment of research and development, for products or services with a realistic chance, it should be capitalized and not expensed. Investors need to be aware of the differences in how businesses capitalize or expense their research and development spending, since, without additional financial analysis, it’s important to factor in research and development equally. This is because companies that don’t capitalize experience more unstable earnings.
Exploring Capitalization Versus Expensing
To determine the value and to capitalize such assets, analysts must project the asset’s lifespan to produce benefits (over its economic life) and go with that projection for the amortization period.
Amortization life varies between assets and is based on the economic life of the particular asset. Ways to determine the economic life depend on both the asset’s patentability and/or salability. If there’s a pharmaceutical drug with a 20-year patent, it’ll likely have a much longer life than the next mobile device or graphic processing unit (GPU).
Assuming an asset has a life of six years, the business would amortize equally over the six-year time frame. There can be a multitude of amortization approaches, but the straight-line method is used for the capitalized research and development expenses. It assumes the following figures:
$200,000 spent on R&D
$40,000 residual value
Based on the difference of $160,000 and the six-year economic life, each year would result in approximately $26,666 in amortization expense. After six years, the resulting value would be $40,000 in residual value.
Conclusion
Understanding the importance of accounting for R&D outlays is helpful for businesses to maximize investments for competitiveness and financial compliance.

Rescissions Act of 2025 (HR 4) – A rescission bill cancels funding previously approved by Congress upon request by the president. Congress has 45 continuous legislative days to enact or reject the proposal, during which time the funds may be temporarily withheld. Introduced by Rep. Steve Scalise (R-LA) on June 6, the House passed this bill on June 12 and the Senate passed it on July 17. Signed into law on July 24, this bill cancels nearly $9 billion in funding for a variety of programs, including foreign aid and the Corporation for Public Broadcasting.
Artificial intelligence (AI) is one of the most talked-about technologies today. It has taken a shift from the broad general-purpose tools to specialized innovations that promise real impact. AI is dominating headlines with investor pitches. There has also been a surge in startups promising AI-powered solutions. However, some businesses have already adopted and invested millions into AI projects with little return. As AI advances, business owners and investors need to stop chasing the latest headlines and consider how to best integrate AI to create lasting value.
Life insurance is something most of us don’t want to talk about. But the truth is, no one gets out of life alive. So, it might make sense to face it now so that when you really need it, it’s there. Before you start looking for a life insurance policy, let’s dispel some of the untruths you might have heard.
According to the Federal Reserve Bank of St. Louis, collection agencies saw $16.28 billion in revenue in 2019. While revenues have declined somewhat in recent years, unpaid invoices are still big business. Accounts receivable aging reports can help companies identify and mitigate unpaid invoices and potentially lower a business’ need to send unpaid invoices to collection agencies.
Required minimum distributions (RMDs) from traditional IRAs and 401(k)s often become a significant tax burden during retirement. As the percentage of your IRA that must be distributed increases each year, many retirees face higher adjusted gross income and increased exposure to stealth taxes. However, with strategic planning, you can transform RMDs from burdens into opportunities.